OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
95013055

Access Bio Inc

Medical Equipment, Supplies & DistributionVerified

Access Bio Inc maintains a strong liquidity position with a current ratio of 10.11, indicating that it holds significantly more current assets than current liabilities. However, the company has a negative net cash position after subtracting total debt, which introduces a medium liquidity risk. The company's debt-to-equity ratio is 0.12, suggesting a conservative capital structure with limited leverage. Profitability metrics show that Access Bio Inc has a return on equity (ROE) of 0.0045 and a return on assets (ROA) of 0.0039. These figures are below the typical thresholds for strong performance in the medical equipment and supplies industry, indicating that the company is not generating substantial returns relative to its equity and asset base. The company's revenue is not segmented by product or geographic region in the available data, so it is not possible to assess the concentration of revenue across different business lines or geographic markets. However, the lack of segmentation data suggests that the company may have a relatively undiversified revenue stream. Access Bio Inc reported revenue of $26,428,840 in the latest period. The company's growth trajectory is not clearly defined in the available data, as there are no forward-looking revenue projections or historical growth rates provided. The absence of capital expenditures and the low level of operating cash flow suggest that the company is not currently investing heavily in expansion or new projects. The company faces a medium liquidity risk due to its negative net cash position after subtracting total debt. While the dilution risk is currently low, the company's conservative capital structure and limited leverage may constrain its ability to raise additional capital if needed. No specific dilution sources are identified in the available data. Recent financial filings and transcripts do not provide additional insights into the company's operations or strategic direction. The available data is limited to basic financial metrics and does not include detailed management commentary or forward-looking guidance.

30-day price · 950130+625.00 (+22.6%)
Low$2695.00High$4705.00Close$3395.00As of15 May, 00:00 UTC
Profile
CompanyAccess Bio Inc
Ticker950130.KQ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Access Bio Inc is a medical equipment and supplies company that generates revenue primarily through the sale of diagnostic and healthcare products.

Classification. Access Bio Inc is classified under the industry "Medical Equipment, Supplies & Distribution" within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

Access Bio Inc maintains a strong liquidity position with a current ratio of 10.11, indicating that it holds significantly more current assets than current liabilities. However, the company has a negative net cash position after subtracting total debt, which introduces a medium liquidity risk. The company's debt-to-equity ratio is 0.12, suggesting a conservative capital structure with limited leverage. Profitability metrics show that Access Bio Inc has a return on equity (ROE) of 0.0045 and a return on assets (ROA) of 0.0039. These figures are below the typical thresholds for strong performance in the medical equipment and supplies industry, indicating that the company is not generating substantial returns relative to its equity and asset base. The company's revenue is not segmented by product or geographic region in the available data, so it is not possible to assess the concentration of revenue across different business lines or geographic markets. However, the lack of segmentation data suggests that the company may have a relatively undiversified revenue stream. Access Bio Inc reported revenue of $26,428,840 in the latest period. The company's growth trajectory is not clearly defined in the available data, as there are no forward-looking revenue projections or historical growth rates provided. The absence of capital expenditures and the low level of operating cash flow suggest that the company is not currently investing heavily in expansion or new projects. The company faces a medium liquidity risk due to its negative net cash position after subtracting total debt. While the dilution risk is currently low, the company's conservative capital structure and limited leverage may constrain its ability to raise additional capital if needed. No specific dilution sources are identified in the available data. Recent financial filings and transcripts do not provide additional insights into the company's operations or strategic direction. The available data is limited to basic financial metrics and does not include detailed management commentary or forward-looking guidance.
Key takeaways
  • Access Bio Inc has a strong current ratio of 10.11, indicating a robust short-term liquidity position.
  • The company's return on equity and return on assets are below typical industry benchmarks, suggesting limited profitability.
  • The company's capital structure is conservative, with a debt-to-equity ratio of 0.12.
  • Access Bio Inc has a negative net cash position after subtracting total debt, introducing a medium liquidity risk.
  • The company's growth trajectory is not clearly defined in the available data.
  • The company's revenue is not segmented by product or geographic region, indicating a potentially undiversified revenue stream.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$26.4M
Gross profit$13.5M
Operating income$1.6M
Net income$2.0M
R&D
SG&A
D&A
SBC
Operating cash flow$35.0M
CapEx-$155.0k
Free cash flow$5.2M
Total assets$529.0M
Total liabilities$79.4M
Total equity$449.6M
Cash & equivalents
Long-term debt$55.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$441.4M$227.1M$165.8M$142.4M
FY-3$800.2M$363.1M$268.3M$264.4M
FY-2$267.1M$18.0M-$2.4M-$28.9M
FY-1$82.5M-$4.1M-$254.8k$11.5M
FY0$22.0M-$76.9M-$57.7M-$47.7M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$372.8M$241.7M
FY-3$698.7M$487.7M
FY-2$536.0M$453.0M
FY-1$504.0M$442.3M
FY0$423.7M$388.3M$225.2M
PeriodOCFCapExFCFSBC
FY-4$137.9M-$28.8M$142.4M
FY-3$291.3M-$14.9M$264.4M
FY-2-$80.6M-$14.4M-$28.9M
FY-1$13.5M-$1.4M$11.5M
FY0-$20.3M-$1.2M-$47.7M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$26.4M$1.6M$2.0M$5.2M
FQ-6$18.6M-$1.9M$1.1M$3.2M
FQ-5$16.0M-$6.1M-$3.5M-$429.8k
FQ-4$21.4M$2.3M$75.7k$3.5M
FQ-3$14.9M-$5.7M-$4.5M-$1.9M
FQ-2$962.8k-$13.6M-$7.4M-$4.4M
FQ-1$2.5M-$9.8M-$8.0M-$5.2M
FQ0$3.6M-$47.8M-$37.8M-$36.2M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$529.0M$449.6M
FQ-6$520.5M$446.6M$240.8M
FQ-5$519.3M$456.2M$235.2M
FQ-4$504.0M$442.3M
FQ-3$490.6M$438.8M$243.2M
FQ-2$491.8M$441.0M$240.1M
FQ-1$479.2M$428.8M$223.3M
FQ0$423.7M$388.3M$225.2M
PeriodOCFCapExFCFSBC
FQ-7$35.0M-$155.0k$5.2M
FQ-6$26.8M-$1.3M$3.2M
FQ-5$18.0M-$1.4M-$429.8k
FQ-4$13.5M-$1.4M$3.5M
FQ-3$5.4M-$635.1k-$1.9M
FQ-2-$966.4k-$732.5k-$4.4M
FQ-1-$19.0M-$1.2M-$5.2M
FQ0-$20.3M-$1.2M-$36.2M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$449.6M
Net cash-$55.1M
Current ratio10.1
Debt/Equity0.1
ROA0.4%
ROE0.4%
Cash conversion17.1%
CapEx/Revenue-0.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
Metric950130Activity
Op margin6.2%3.9% medp25 -31.3% · p75 14.4%above median
Net margin7.7%2.4% medp25 -30.5% · p75 11.1%above median
Gross margin51.0%46.7% medp25 28.2% · p75 63.1%above median
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-0.6%-4.8% medp25 -11.6% · p75 -2.4%top quartile
Debt / equity12.0%17.9% medp25 2.7% · p75 52.2%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 09:57 UTC#1b3840fb
Market quoteclose USD 3210.00 · shares 0.04B diluted
no public URL
2026-05-10 09:57 UTC#80360058
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 05:03 UTCJob: 700c0861